Titan Pharmaceuticals Stock Price, News & Analysis (NASDAQ:TTNP) $0.35 +0.02 (+6.06%) (As of 11/30/2023 ET) Add Compare Share Share Today's Range$0.34▼$0.3550-Day Range$0.33▼$0.5052-Week Range$0.31▼$1.09Volume3,734 shsAverage Volume20,741 shsMarket Capitalization$5.27 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media About Titan Pharmaceuticals Stock (NASDAQ:TTNP)Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in the United States, Canada, and the European Union. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder; and other programs, including HIV preventative therapeutic and a contraceptive from a single ProNeura implant for women and adolescent girls. The company was incorporated in 1992 and is based in South San Francisco, California.Read More TTNP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TTNP Stock News HeadlinesNovember 26, 2023 | americanbankingnews.comHead to Head Survey: Titan Pharmaceuticals (NASDAQ:TTNP) vs. Ignyte Acquisition (NASDAQ:IGNY)November 23, 2023 | americanbankingnews.comTitan Pharmaceuticals (NASDAQ:TTNP) Coverage Initiated at StockNews.comDecember 1, 2023 | Tomorrow Investor (Ad)The Only Practical Solution to the World’s Looming Energy CrisisThere’s just one problem: There are more plans for new uses of nuclear than there is uranium to fuel the plants!October 16, 2023 | finance.yahoo.comTitan Pharmaceuticals Announces Appointment of Dato' Seow Gim Shen and Brynner Chaim to the Company's Board of DirectorsSeptember 18, 2023 | seekingalpha.comTitan Pharmaceuticals reports $9.5M private placement of convertible preferred stockSeptember 18, 2023 | finance.yahoo.comTitan Pharmaceuticals Announces $9.5 Million Private Placement of Convertible Preferred StockAugust 28, 2023 | finance.yahoo.comUnveiling Titan Pharmaceuticals (TTNP)'s Value: Is It Really Priced Right? A Comprehensive GuideAugust 13, 2023 | thestreet.comTitan Pharmaceuticals (TTNP) Stock Soars on FDA Committee Treatment ApprovalDecember 1, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. July 27, 2023 | finance.yahoo.comTitan Pharmaceuticals Announces Sale of Certain ProNeura AssetsJune 29, 2023 | usatoday.comPatents, lawsuits, safety concerns — then tragedy. A timeline of OceanGate's Titan sub.May 26, 2023 | finance.yahoo.comTTNP - Titan Pharmaceuticals, Inc.May 23, 2023 | sports.yahoo.comWatch: Prowling tiger bows to ‘titan herd’ of elephantsMarch 22, 2023 | seekingalpha.comTTNP Titan Pharmaceuticals, Inc.December 15, 2022 | finance.yahoo.comTitan Pharmaceuticals Provides Shareholder UpdateDecember 12, 2022 | nz.finance.yahoo.comTitan Pharmaceuticals Inc. Announces Licensing Agreement with Ocular Therapeutix Inc.November 21, 2022 | bizjournals.comChapel Hill surgical tech company shapes plan to keep Nasdaq listingNovember 17, 2022 | finance.yahoo.comTitan Pharmaceuticals Third Quarter 2022 Earnings: US$0.18 loss per share (vs US$0.19 loss in 3Q 2021)November 4, 2022 | msn.comTitan, GAIL, TVS Motor, Britannia & Other Stocks to Release Q2 Results TodayAugust 17, 2022 | benzinga.comTitan Pharmaceuticals Announces Board Expansion...August 16, 2022 | finance.yahoo.comTitan Pharmaceuticals Announces Board Expansion and Management ChangesJuly 11, 2022 | insidermonkey.comHedge Fund and Insider Trading News: George Soros, Jim Simons, Three Arrows Capital, Rocket Companies Inc (RKT), Titan Pharmaceuticals, Inc. (TTNP), and MoreJuly 11, 2022 | finance.yahoo.comActivist Investing Nominates Slate of Highly Qualified Director Candidates for Election to the Board of Directors of Titan Pharmaceuticals at Upcoming Special Meeting of StockholdersJuly 9, 2022 | finance.yahoo.comHere's Why We're Watching Titan Pharmaceuticals' (NASDAQ:TTNP) Cash Burn SituationJuly 6, 2022 | benzinga.comTitan Pharmaceuticals Gets FDA Clearance To Commence Opioid Disorder StudyJuly 5, 2022 | nasdaq.comTitan Pharma Says FDA Clears IND Application For Nalmefene ImplantJuly 5, 2022 | finance.yahoo.comTitan Pharmaceuticals Announces FDA Clearance of IND Application for Nalmefene ImplantSee More Headlines Receive TTNP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Titan Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/30/2021Today12/01/2023Fiscal Year End12/31/2023Next Earnings (Estimated)2/13/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TTNP CUSIPN/A CIK910267 Webwww.titanpharm.com Phone(650) 244-4990Fax650-244-4956Employees4Year Founded1992Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-10,210,000.00 Net Margins-2,021.31% Pretax Margin-2,021.31% Return on Equity-302.61% Return on Assets-144.74% Debt Debt-to-Equity RatioN/A Current Ratio5.30 Quick Ratio5.30 Sales & Book Value Annual Sales$560,000.00 Price / Sales9.42 Cash FlowN/A Price / Cash FlowN/A Book Value$0.54 per share Price / Book0.65Miscellaneous Outstanding Shares15,070,000Free Float10,863,000Market Cap$5.27 million OptionableOptionable Beta1.41 Social Links Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. David Elliot Lazar (Age 32)CEO & Principal Financial Officer Comp: $726.08kDr. Katherine L. Beebe-DeVarney Ph.D. (Age 62)President, COO & Director Comp: $308kMr. Mike FritzNational Sales DirectorJennifer KiernanExecutive Assistant to CEO & Investor Communications CoordinatorJoe SchreiExecutive Director of Commercial OperationsKey CompetitorsCreative Medical TechnologyNASDAQ:CELZAdial PharmaceuticalsNASDAQ:ADILCohBarNASDAQ:CWBRInVivo TherapeuticsNASDAQ:NVIVDermata TherapeuticsNASDAQ:DRMAView All CompetitorsInsidersDavid E. LazarSold 3,388,902 sharesTotal: $4.17 M ($1.23/share)David E LazarBought 37,500 shares on 1/24/2023Total: $36,375.00 ($0.97/share)View All Insider Transactions TTNP Stock Analysis - Frequently Asked Questions How have TTNP shares performed in 2023? Titan Pharmaceuticals' stock was trading at $0.7831 at the beginning of 2023. Since then, TTNP stock has decreased by 55.3% and is now trading at $0.35. View the best growth stocks for 2023 here. When is Titan Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 13th 2024. View our TTNP earnings forecast. How were Titan Pharmaceuticals' earnings last quarter? Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) posted its quarterly earnings results on Tuesday, March, 30th. The specialty pharmaceutical company reported ($0.86) EPS for the quarter, topping the consensus estimate of ($1.33) by $0.47. Titan Pharmaceuticals had a negative net margin of 2,021.31% and a negative trailing twelve-month return on equity of 302.61%. When did Titan Pharmaceuticals' stock split? Titan Pharmaceuticals shares reverse split on Tuesday, December 1st 2020. The 1-30 reverse split was announced on Monday, November 30th 2020. The number of shares owned by shareholders was adjusted after the market closes on Monday, November 30th 2020. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. What other stocks do shareholders of Titan Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Titan Pharmaceuticals investors own include Bionano Genomics (BNGO), Gran Tierra Energy (GTE), Matinas BioPharma (MTNB), Organigram (OGI), Zosano Pharma (ZSAN), Novan (NOVN), ADMA Biologics (ADMA), Aeterna Zentaris (AEZS), CNBX Pharmaceuticals (CNBX) and Pennsylvania Real Estate Investment Trust (PEI). Who are Titan Pharmaceuticals' major shareholders? Titan Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%). View institutional ownership trends. How do I buy shares of Titan Pharmaceuticals? Shares of TTNP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:TTNP) was last updated on 12/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Titan Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.